Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
Active, not recruiting · Phase 2 · NCT02682511
Conditions: Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
At a glance
- Research payments reported, 2025
- $76,004
- U.S. investigators named
- 8
- Sites paid
- 8
- Planned or actual enrollment
- 34
About the trial
- Sponsor
- Cumberland Pharmaceuticals
- Tested
- Oral Ifetroban (drug), Oral Placebo (drug)
- Dates
- Started 2017-01; completion 2026-09
- Results posted
- Not yet
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).
From ClinicalTrials.gov, last updated 2026-09-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Cumberland Pharmaceuticals, Inc. reported $76,004 in research payments for this study in 2025 (18 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Suzanne Kafaja, M.D. Rheumatology · Los Angeles, CA
- Flavia V. Castelino, M.D. Rheumatology · Boston, MA
- Laura Hummers, M.D. Rheumatology · Baltimore, MD
- Tammy O. Wichman, M.D. Critical Care Medicine · Omaha, NE
- Jessica K. Gordon, MD Internal Medicine · New York, NY
- Robyn Domsic Rheumatology · Pittsburgh, PA
- Fabian A. Mendoza Ballesteros, M.D Rheumatology · Philadelphia, PA
- Susan K. Mathai, M.D. Pulmonology · Dallas, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Nebraska Medical Center $26,029
- Thomas Jefferson University $19,829
- UPMC $8,506
- Johns Hopkins Hospital, the, MD $7,705
- UC Regents $4,568
- Baylor Research Institute $4,029
- Mgh Rheumatology $3,500
- Hospital for Special Surgery, NY $1,838
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.